Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Melanie D Everitt, Elfriede Pahl, Devin A Koehl, Ryan S Cantor, James K Kirklin, Amy Christine Reed, Philip Thrush, Matthew Zinn, Amanda D McCormick, Jessie Yester, Jenna S Schauer, Donna W Lee
BACKGROUND: Extending graft survival after heart transplant (HT) is of paramount importance to achieve survival well into adulthood for childhood recipients. Acute rejection is a significant adverse event, and biopsy remains the most specific means for diagnosing acute cellular rejection (ACR) versus antibody-mediated rejection (AMR). METHODS: All children in the Pediatric Heart Transplant Society (PHTS) Registry who underwent HT between 1/2015 and 6/2022 and had ≥1 episode of treated rejection were included...
September 3, 2024: Journal of Heart and Lung Transplantation
#2
JOURNAL ARTICLE
Stephan Rosenkranz, Hossein-Ardeschir Ghofrani, Marius M Hoeper, David Langleben, Sara Hegab, Claudia Rahner, Jean-François Richard, Vallerie V McLaughlin
BACKGROUND: There is limited evidence to support treatment recommendations in patients with pulmonary arterial hypertension (PAH) and comorbidities. To investigate the impact of riociguat treatment in this patient population we analyzed pooled data from randomized controlled trials of riociguat. METHODS: This post hoc analysis included data from the PATENT-1, PATENT-2, PATENT PLUS, and REPLACE studies. Safety, efficacy (6-minute walk distance [6MWD], World Health Organization functional class [WHO-FC], and N-terminal pro-brain natriuretic peptide [NT-proBNP]), and COMPERA 2...
September 3, 2024: Journal of Heart and Lung Transplantation
#3
JOURNAL ARTICLE
Raymond L Benza, Kelly M Chin, Sean Gaine, Nazzareno Galiè, Marius M Hoeper, Irene M Lang, Vallerie V McLaughlin, Olivier Sitbon, Gurinderpal Doad, Joseph Yen, Xiaoqin Tang, Victor Tapson
BACKGROUND: Mortality risk assessment informs clinical management of pulmonary arterial hypertension (PAH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 is a simplified risk calculator discriminating 1-year mortality risk. METHODS: This post-hoc analysis of the phase 3 GRIPHON study assessed changes in REVEAL Lite 2 risk score with selexipag versus placebo, and whether changes were prognostic or predictive of time to first morbidity/mortality (M/M) event...
August 31, 2024: Journal of Heart and Lung Transplantation
#4
JOURNAL ARTICLE
Shin Lin, Ioannis Dimarakis, Elina Minami, Ramasamy Bakthavatsalam, Renuka Bhattacharya, April Stempien-Otero, Yiing Lin, Aris Karatasakis, Maziar Khorsandi, Elaine Chou-Wu, Idoia Gimferrer, Mariya Y Golub, Richard K Cheng, Ryutaro Hirose, Mark Sturdevant, Jay D Pal
For patients with end stage heart disease and borderline hemodynamics, high HLA allosensitization presents a barrier for heart transplantation in a timely manner. Conventional desensitization protocols are inadequate in this context due to time constraints and for the most highly reactive immunologically. We previously reported performing heart after liver transplant with domino liver transplant (HALT-D) on a single patient without liver disease. We describe this patient's course to date as well as four subsequent patients listed for this novel therapy...
August 31, 2024: Journal of Heart and Lung Transplantation
#5
JOURNAL ARTICLE
Dag Edström, Anna Niroomand, Martin Stenlo, Ellen Broberg, Gabriel Hirdman, Haider Ghaidan, Snejana Hyllén, Leif Pierre, Franziska Olm, Sandra Lindstedt
BACKGROUND: Lung transplantation is hindered by low donor lung utilization rates. Infectious complications are reasons to decline donor grafts due to fear of post-transplant primary graft dysfunction. Mesenchymal stem cells are a promising therapy currently investigated in treating lung injury. Full-term amniotic fluid-derived lung-specific mesenchymal stem cell treatment may regenerate damaged lungs. These cells have previously demonstrated inflammatory mediation in other respiratory diseases, and we hypothesized that treatment would improve donor lung quality and post-operative outcomes...
August 23, 2024: Journal of Heart and Lung Transplantation
#6
EDITORIAL
Michael J Simmonds, Bente Thamsen, Salim E Olia, Antony P McNamee, Marcus Granegger, Hendrik Wurm, Keshava Rajagopal, David C McGiffin
Mechanical circulatory support devices have profoundly transformed the management of severe cardiothoracic disorders. While heart transplantation is the gold standard therapy for end stage heart disease, long-term mechanical support devices are a viable alternative for those ineligible and/or those awaiting organ availability. Major technological advancements were made over first five decades of development, resulting in improved durability and survival with reduced adverse events. However, gains have tapered recently for various complications (e...
August 23, 2024: Journal of Heart and Lung Transplantation
#7
LETTER
Savitri Fedson, Kelly Bryce, Andrew Courtwright, Jon Dark, Tom Egan, Are Martin Holm, Olivia Kates, Jacob Lavee, Anne Olland
No abstract text is available yet for this article.
August 22, 2024: Journal of Heart and Lung Transplantation
#8
EDITORIAL
Maria T Gamero, Yevgeniy Brailovsky, Howard J Eisen
No abstract text is available yet for this article.
August 17, 2024: Journal of Heart and Lung Transplantation
#9
LETTER
Konrad Hoetzenecker, Caitlin Demarest, Philippe Lemaitre, Stephanie H Chang, Marcelo Cypel, Matthew Bacchetta
No abstract text is available yet for this article.
August 13, 2024: Journal of Heart and Lung Transplantation
#10
JOURNAL ARTICLE
Jennifer A Cowger, Ezequiel Molina, Luqin Deng, Manreet Kanwar, Palak Shah, Rebecca Cogswell, Igor Gosev, Ryan S Cantor, Todd F Dardas, James K Kirklin, Joseph G Rogers, Joseph C Cleveland, Kristin E Sandau, Colleen K McIlvennan, David Kaczorowski, Jerry D Estep, Francis D Pagani
BACKGROUND: Patients have substantial variability in perioperative outcomes after left ventricular assist device (LVAD) implant. A perioperative multidimensional tool integrating mortality, adverse events (AEs), and patient-reported outcomes to assist in quality improvement initiatives is needed. METHODS: Patients undergoing HeartMate 3 LVAD implant (1/1/2017 and 1/31/2024) in the Society of Thoracic Surgeons' Intermacs registry were studied. A Cox proportional hazard multivariable analysis incorporating AEs as time-varying covariates for mortality out to 180 days was used to generate the Intermacs Short-Term Composite Quality (INSITE) score, reflecting the adjusted hazard ratio (HR) for mortality contributed by each AE, applying global ranking methodology...
August 12, 2024: Journal of Heart and Lung Transplantation
#11
JOURNAL ARTICLE
Denny Choi, Michelle North, Musawir Ahmed, Natalia Belousova, Anastasiia Vasileva, John Matelski, Lianne G Singer, Joyce K Y Wu, Cheol-Heon Jeong, Greg Evans, Chung-Wai Chow
BACKGROUND: Exposure to air pollution post lung transplant has been shown to decrease graft and patient survival. This study examines the impact of air pollution exposure in the first 3 months post-transplant on baseline (i.e. highest) forced expiratory volume in 1s (FEV1 ) achieved and development of chronic lung allograft dysfunction (CLAD). METHODS: Double-lung transplant recipients (n=82) were prospectively enrolled for comprehensive indoor and personal environmental monitoring at 6- and 12-weeks post-transplant and followed for >4 years...
August 12, 2024: Journal of Heart and Lung Transplantation
#12
JOURNAL ARTICLE
Isabelle Etienne, Delphine Kemlin, Nicolas Gemander, Véronique Olislagers, Alexandra Waegemans, Emilie Dhondt, Leo Heyndrickx, Stéphanie Depickère, Alexia Charles, Maria Goossens, Leen Vandermosten, Isabelle Desombere, Kevin K Ariën, Pieter Pannus, Christiane Knoop, Arnaud Marchant
Lung transplant recipients (LTR) are susceptible to severe COVID-19 and had lower immune responses to primary SARS-CoV-2 vaccination as compared to the general population and to other solid organ transplant recipients. As immunity induced by booster vaccination and natural infection has increased since the beginning of the pandemic in the general population, immunity acquired by LTR is not well documented. Humoral and cellular immunity to SARS-CoV-2 was monitored in February and May 2023 in 30 LTR and compared to that of health care workers (HCW) and nursing home residents (NHR)...
August 10, 2024: Journal of Heart and Lung Transplantation
#13
JOURNAL ARTICLE
Jennifer Conway, Tara Pidborochynski, Diana Ly, Leah Mowat, Darren H Freed, Izak De Villiers Jonker, Mohammed Al-Aklabi, Paula Holinski, Vijay Anand, Holger Buchholz
For smaller pediatric patients on ventricular assist devices (VADs), the Berlin Heart EXCOR® remains the main form of durable support. It requires a connection to the external IKUS which has limited portability and battery life. The new EXCOR® Active mobile driving unit has battery life up to 13 hours. We describe the first North American experience with the EXCOR® Active in pediatric patients with a Berlin Heart device. Retrospective chart review was undertaken. Between Oct/2022 to Mar/2024, seven patients were on a Berlin Heart and supported with the EXCOR® Active...
August 10, 2024: Journal of Heart and Lung Transplantation
#14
JOURNAL ARTICLE
Yael Peled, Anique Ducharme, Michelle Kittleson, Neha Bansal, Josef Stehlik, Shahnawaz Amdani, Diyar Saeed, Richard Cheng, Brian Clarke, Fabienne Dobbels, Maryjane Farr, JoAnn Lindenfeld, Lazaros Nikolaidis, Jignesh Patel, Deepak Acharya, Dimpna Albert, Saima Aslam, Alejandro Bertolotti, Michael Chan, Sharon Chih, Monica Colvin, Maria Crespo-Leiro, David D'Alessandro, Kevin Daly, Carles Diez-Lopez, Anne Dipchand, Stephan Ensminger, Melanie Everitt, Alexander Fardman, Marta Farrero, David Feldman, Christiana Gjelaj, Matthew Goodwin, Kimberly Harrison, Eileen Hsich, Emer Joyce, Tomoko Kato, Daniel Kim, Me-Linh Luong, Haifa Lyster, Marco Masetti, Ligia Neres Matos, Johan Nilsson, Pierre-Emmanuel Noly, Vivek Rao, Katrine Rolid, Kelly Schlendorf, Martin Schweiger, Joseph Spinner, Madeleine Townsend, Maxime Tremblay-Gravel, Simon Urschel, Jean-Luc Vachiery, Angela Velleca, Georgina Waldman, James Walsh
The "International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024" updates and replaces the "Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006" and the "2016 International Society for Heart Lung Transplantation Listing Criteria for Heart Transplantation: A 10-year Update." The document aims to provide tools to help integrate the numerous variables involved in evaluating patients for transplantation, emphasizing updating the collaborative treatment while waiting for a transplant...
August 8, 2024: Journal of Heart and Lung Transplantation
#15
JOURNAL ARTICLE
Kevin J Clerkin, Lorenzo Sewanan, Jan M Griffin, Ersilia DeFilippis, Boyu Peng, Margarita Chernovolenko, Erin Harris, Nikil Prasad, Paolo C Colombo, Melana Yuzefpolskaya, Justin Fried, Jayant Raikhelkar, Veli K Topkara, Michelle Castillo, Elaine Y Lam, Farhana Latif, Koji Takeda, Nir Uriel, Gabriel Sayer, Andrew J Einstein
BACKGROUND: Cardiac hybrid positron emission tomography/computed tomography (PET/CT) has become a valid screening modality for cardiac allograft vasculopathy (CAV) following HT. Visually estimated coronary artery calcium (VECAC) can be quantified from CT images obtained as part of PET/CT and has been shown to be associated with adverse cardiovascular outcomes in coronary artery disease. We investigated the prognostic value of VECAC following heart transplantation (HT). METHODS: A retrospective analysis of 430 consecutive adult HT patients who underwent 13 N-ammonia cardiac PET/CT from 2016-2019 with follow-up through October 15, 2022, was performed...
August 7, 2024: Journal of Heart and Lung Transplantation
#16
JOURNAL ARTICLE
Erik J Henricksen, Brian Wayda, Jeffrey J Teuteberg, Helen Luikart, Joyce Njoroge, Brandon A Guenthart, Kiran K Khush
BACKGROUND: Patients of advanced age are often considered to be poor candidates for heart transplant (HT). As the U.S. population continues to age, it is important for clinicians to understand how best to select patients for advanced therapies. METHODS: This was a retrospective analysis of the U.S. Scientific Registry of Transplant Recipients data from 2006 to August 2022 in adult recipients. Patients were excluded if they were multiorgan transplant, re-do transplants, or less than 1 year post transplant...
August 7, 2024: Journal of Heart and Lung Transplantation
#17
JOURNAL ARTICLE
Het Patel, Leonie Dupuis, Matthew Bacchetta, Antonio Hernandez, Manreet K Kanwar, JoAnn Lindenfeld, Zubair Shah, Hasan K Siddiqi, Shashank S Sinha, Ashish S Shah, Kelly H Schlendorf, Aniket S Rali
BACKGROUND: Utilization of temporary mechanical circulatory support including veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) as a bridge to heart transplantation (HT) has increased significantly under the revised United Network for Organ Sharing (UNOS) donor heart allocation system since October 2018. The revised heart allocation system aimed to lower waitlist times and mortality for the most critically ill patients requiring bi-ventricular, non-dischargeable, mechanical circulatory support...
August 7, 2024: Journal of Heart and Lung Transplantation
#18
LETTER
R Moayedifar, A Zuckermann
No abstract text is available yet for this article.
August 5, 2024: Journal of Heart and Lung Transplantation
#19
JOURNAL ARTICLE
Ei Miyamoto, Daniel Vosoughi, Jinguo Wang, Jamal Al-Refaee, Gregory Berra, Tina Daigneault, Allen Duong, Betty Joe, Sajad Moshkelgosha, Shaf Keshavjee, Kathryn Tinckam, David Hwang, Andrzej Chruscinski, Stephen Juvet, Tereza Martinu
INTRODUCTION: Donor human leukocyte antigen (HLA)-specific antibodies (DSA) and non-HLA antibodies can cause allograft injury, possibly leading to chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx). It remains unclear whether these antibodies are produced locally in the graft or derived solely from circulating plasma cells. We hypothesized that DSA and non-HLA antibodies are produced in CLAD lungs. METHODS: Lung tissue was prospectively collected from 15 CLAD patients undergoing re-LTx or autopsy...
August 1, 2024: Journal of Heart and Lung Transplantation
#20
JOURNAL ARTICLE
Ryan Chaban, Ikechukwu Ileka, Gannon McGrath, Kohei Kinoshita, Zahra Habibabady, Madelyn Ma, Victoria Diaz, Akihiro Maenaka, Anthony Calhoun, Megan Dufault, Ivy Rosales, Christiana M Laguerre, Seyed-Amir Sanatkar, Lars Burdorf, David L Ayares, William Eyestone, Prachi Sardana, Kasinath Kuravi, Lori Sorrells, Seth Lederman, Caroline G Lucas, Randall S Prather, Kevin D Wells, Kristin M Whitworth, David Kc Cooper, Richard N Pierson Iii
BACKGROUND: Xenotransplantation has made significant advances recently using pigs genetically engineered to remove carbohydrate antigens, either alone or with addition of various human complement, coagulation, and anti-inflammatory 'transgenes'. Here we evaluated results associated with gene-edited (GE) pig hearts transplanted in baboons using an established costimulation-based immunosuppressive regimen and a cold-perfused graft preservation technique. METHODS: Eight baboons received heterotopic abdominal heart transplants from 3-GE (GalKO...
August 1, 2024: Journal of Heart and Lung Transplantation
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
